Fast-growing Zymergen grabs landmark former Chiron space

Fast-growing Zymergen grabs landmark former Chiron space

Zymergen employs more than 800. The company launched in 2013 in a QB3 incubator in San Francisco.

Meissa Vaccines Raises $30M to Advance RSV Vaccine into Clinical Trials

Meissa Vaccines Raises $30M to Advance RSV Vaccine into Clinical Trials

The funding will expand the team, enable clinical trials for Meissa’s investigational vaccine, and support a viral vaccine pipeline.

Glycomine raises $33 million for rare disease therapeutics

Glycomine raises $33 million for rare disease therapeutics

Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding.

Prellis raises $8.7 million for 3D-printed organs

Prellis raises $8.7 million for 3D-printed organs

The ultimate goal is to 3D print the entire vascular system of a kidney in 12 hours or less.

BASF is collaborating with Riffyn on white biotechnology R&D

BASF is collaborating with Riffyn on white biotechnology R&D

A next-generation global data platform to advance development of bio-based solutions and fermentation processes.

MedaRed Raises $6.5 Million for Therapeutics Targeting Fibrin

MedaRed Raises $6.5 Million for Therapeutics Targeting Fibrin

The company’s initial focus will be on Alzheimer’s and multiple sclerosis.

Encoded Nabs $104M & Illumina’s Help to Push Gene Therapy’s Limits

DNA-DSB-Depositphotos_193598822_original-resize_edited-4x3-e1553169839404-1100x734.jpg

Despite the progress of gene therapy—a cutting edge medicine promising long-lasting effects from a single treatment—it remains a crude and limited tool. Startup Encoded Therapeutics has raised $104 million to join the race to expand gene therapy’s reach.

The South San Francisco, CA, company has emerged from the startup accelerator of Illumina (NASDAQ: ILMN), and it counts the DNA sequencing giant among its investors along with Arch Venture Partners, Venrock, and others. The $104 million haul it closed today brings its total funding to $158 million and will back human tests of a gene therapy for a rare form of epilepsy called Dravet syndrome.

The Dravet program is meant to show that Encoded, using an atypical approach that harnesses DNA sequencing and computing tools, can get to diseases that gene therapy currently can’t touch. Its proof so far is only in animal tests. Human studies of the Dravet program should begin by early 2021, says CEO Kartik Ramamoorthi.

Read more at Xconomy

Aromyx Corp. Closes $3 million Investment

Aromyx Corp. Closes $3 million Investment

The company will grow its team and continue development of its sensory platform to digitally measure taste and smell.

Biopharma firm Atreca goes public

Biopharma firm Atreca goes public

Atreca uses its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.

Riffyn Raises a $15M Series B to Accelerate Its Growth in Life Sciences R&D

Riffyn Raises a $15M Series B to Accelerate Its Growth in Life Sciences R&D

The financing will be used by Riffyn to meet surging demand for its R&D data analytics platform.

GigaGen one of "Best Places to Work in the Bay Area"

GigaGen one of "Best Places to Work in the Bay Area"

In the San Francisco Business Times’s annual survey.

BillionToOne Beats the Odds With $15 Million Series A

BillionToOne Beats the Odds With $15 Million Series A

BillionToOne’s first product is a non-invasive prenatal test for recessively inherited single gene disorders.

Prellis Biologics raises $9 million for laser-printing organs

Prellis Biologics raises $9 million for laser-printing organs

Prellis is developing ultra-fast high-resolution holographic laser printing for creating human organs and tissues.

Meissa Vaccines Closes $3.4 Million Round to Advance RSV Vaccine to Clinic

Meissa Vaccines Closes $3.4 Million Round to Advance RSV Vaccine to Clinic

The Meissa team has developed a live attenuated vaccine with global utility.

OncoSynergy submits FDA application for clinical trial of therapy for malignant brain cancer

OncoSynergy submits FDA application for clinical trial of therapy for malignant brain cancer

Glioblastoma is the most common primary brain cancer in adults.

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Last year, Alector advanced two drugs into early-stage clinical testing.

Epalex gets backing for migraine, epilepsy treatments

Epalex gets backing for migraine, epilepsy treatments

Epalex is a member of the 2017 Biotech/Biopharma Pitch Summit cohort.

Maria Artunduaga named Entrepreneur of the Year

Maria Artunduaga named Entrepreneur of the Year

Respira is building a service platform of wearable devices and adaptive digital algorithms to improve the delivery of Chronic Lower Respiratory Disease care.

Zymergen lands $400 million more, led by SoftBank Vision Fund, for its genetically altered microbes

Zymergen lands $400 million more, led by SoftBank Vision Fund, for its genetically altered microbes

The biggest opportunity for the 600-person company is to produce entirely new products that are untethered to traditional petroleum-based manufacturing.